There is no crunching of any data. The JS graphs have been the same since the Symphony data was first initiated. Over 90% coverage by most of the meaningful plans. Same data, just change the brand. The missing data is what is the out of pocket co-pay that is in place for the patient acquisition? Patients will accept up to $50 without much resistance. Once you start going over $75 and into the hundreds, there is a dramatic increase in scripts being abandoned or switched. SUN potential opportunity coverage data has always been a fraud. The key is evaluating probable acquisition that is a factor of cutting deals on co-pay, not a fault of salesmanship. Sales can generate a script. Managed Markets need to ensure that the script has a chance to be filled. The finger pointing over the years has been a hoax.
